Abstract:<p>An estimated 466 million people suffer from hearing loss worldwide. Sensorineural hearing loss is characterized by degeneration of key structures of the sensory pathway in the cochlea such as the sensory hair cells, the primary auditory neurons and their synaptic connection to the hair cells – the ribbon synapse. Various strategies to protect or regenerate these sensory cells and structures are the subject of intensive research. Yet despite recent advances in our understandings of the capacity of the cochlea for repair and regeneration there are currently no pharmacological or biological interventions for hearing loss. Current research focusses on localized cochlear drug, gene and cell-based therapies. One of the more promising drug-based therapies is based on neurotrophic factors for the repair of the ribbon synapse after noise exposure, as well as preventing loss of primary auditory neurons and regrowth of the auditory neuron fibers after severe hearing loss. Drug therapy delivery technologies are being employed to address the specific needs of neurotrophin and other therapies for hearing loss that include the need for high doses, long-term delivery, localised or cell-specific targeting and techniques for their safe and efficacious delivery to the cochlea. Novel biomaterials are enabling high payloads of drugs to be administered to the cochlea with subsequent slow-release properties that are proving to be beneficial for treating hearing loss. In parallel, new gene therapy technologies are addressing the need for cell specificity and high efficacy for the treatment of both genetic and acquired hearing loss with promising reports of hearing recovery. Some biomaterials and cell therapies are being used in conjunction with the cochlear implant ensuring therapeutic benefit to the primary neurons during electrical stimulation. This review will introduce the auditory system, hearing loss and the potential for repair and regeneration in the cochlea. Drug delivery to the cochlea will then be reviewed, with a focus on new biomaterials, gene therapy technologies, cell therapy and the use of the cochlear implant as a vehicle for drug delivery. With the current pre-clinical research effort into therapies for hearing loss, including clinical trials for gene therapy, the future for the treatment for hearing loss is looking bright.</p>

Gene therapy for deafness

Gene therapy for deafness: are we there now?

Recent advances and future challenges in gene therapy for hearing loss

Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges

Gene Therapy for Human Sensorineural Hearing Loss

Milestones toward cochlear gene therapy for patients with hereditary hearing loss

Deafness: from genetic architecture to gene therapy

AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives

Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art

Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success.

Genetic Hearing Loss and Gene Therapy

Gene therapy for hearing loss: challenges and the promise of cellular plasticity and epigenetic modulation

Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems

Current AAV-mediated Gene Therapy in Sensorineural Hearing Loss

Gene therapy: an emerging therapy for hair cells regeneration in the cochlea

Application of Gene Therapy in Auditory System Diseases

Advances in Molecular and Cellular Therapies for Hearing Loss

Gene therapy for hereditary deafness

New molecular therapies for the treatment of hearing loss

Advances in Gene Therapy Hold Promise for Treating Hereditary Hearing Loss